5.98 USD
▲+0.33+8.14%
盘后 5.45 -1.45%
2026-08-03
市值
$835.19M
市盈率
—
EPS
-0.56
股息率
—
52 周区间
1.50 – 5.88
成交量
2.58M
Beta
0.78
目标价
10.00
52W 低 1.5052W 高 5.88
价格走势
公司简介
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational...